• Completed

NCT00507416: Phase 3: Velcade,Thalidomide, Dexamethasone Vs Velcade, Dexamethasone Vs VMP (UPFRONT)

Updated: Apr 25

UPFRONT


NCT00507416: Phase 3: Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone (UPFRONT)


vmp myeloma

Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone (UPFRONT)


This is a randomized, open label, multicenter clinical trial to compare the efficacy and safety of Velcade (bortezomib) and dexamethasone versus Velcade, thalidomide, and dexamethasone versus Velcade, melphalan, and prednisone in patients with previously untreated multiple myeloma not considered candidates for high-dose chemotherapy and autologous stem cell transplantation.


Sponsor:

Millennium Pharmaceuticals, Inc.


Multiple Locations

 

ClinicalTrials.gov Identifier: NCT00507416


Official Title: Randomized Phase 3b Study of Three Treatment Regimens in Subjects With Previously Untreated Multiple Myeloma Who Are Not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation: VELCADE, Thalidomide, and Dexamethasone Versus VELCADE and Dexamethasone Versus VELCADE, Melphalan, and Prednisone

First Posted : July 26, 2007


Click here for details on ClinicalTrials.gov

 

Drug: Bortezomib

Drug: Dexamethasone

Drug: Melphalan

Drug: Prednisone

Drug: Thalidomide

 

J Clin Oncol; 2015

Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens


Although all bortezomib-containing regimens produced good outcomes, VTD and VMP did not appear to offer an advantage over VD in transplantation-ineligible patients with myeloma treated in US community practice.


https://pubmed.ncbi.nlm.nih.gov/26056177/



653. Myeloma - Therapy, excluding Transplantation I| November 18, 2011

Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study


Conclusions: VcD, VcTD, and VcMP induction followed by weekly Vc maintenance produced similar activity in elderly, newly diagnosed, transplant-ineligible MM patients. Patients in the VcD doublet arm appear to have similar long-term outcomes to patients in the VcTD and VcMP triplet arms.


https://doi.org/10.1182/blood.V118.21.478.478







Posts Archive